Stockreport

Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

Applied Therapeutics, Inc.  (APLT) 
Last applied therapeutics, inc. earnings: 11/13 07:00 am Check Earnings Report
PDF AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p AT-007 was well-tolerated; no drug-rel [Read more]